University of Cambridge

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a

In a deal that Aspect Biosystems Ltd. CEO Tamer Mohamed suggested could mean science fiction coming to real life, the Vancouver, BC-based firm focused on bioprinted tissue therapeutics is teaming wi

Who: Exelixis/Storm Therapeutics; Exelixis/Aurigene Discovery What: Exelixis partners with Storm on RNA-modifying enzyme therapies for cancer; the biotech also licenses a non-Hodgkin’s lymphoma can

With $145m in new capital, Apollo Therapeutics LLC is looking to move to the next level by taking its 15-plus preclinical programs sourced from three UK universities into clinical development. As Ap